🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

SUDEEP PHARMA LIMITED SUDEEPPHRM NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.sudeeppharma.com
Company Profile ↓
₹1,329.30
+72.01% 1Y
Mkt Cap₹15,014.26 Cr
P/E85.76
P/B12.24
Div. Yield0.17%
52W High₹1,329.30
52W Low₹529.06
Book Value₹78.21
EPS (TTM)₹15.50

Company Overview

Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in India, the United States, and internationally. The company provides mineral salts, such as iron, calcium, sodium, zinc, copper, magnesium, manganese, potassium, picolinates, simethicone, and others;It also offers micronutrient premixes and liposomal, encapsulated ingredients, spray-dried formats, granulated ingredients, and triturated for sports nutrition, medical and clinical nutrition, infant nutrition, beverages, fortified staples, functional foods, and dairy products. In addition, the company provides a range of mineral powders and granules for carbonated, non-carbonated, and nutraceutical beverages; tricalcium phosphate, dicalcium phophate, dipotassium phosphate, ferric pyrophosphate, and disodium phosphate. Sudeep Pharma Limited was incorporated in 1989 and is based in Vadodara, India.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 19.6%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 24.0%.

Consistent Profit Growth

Net profit has compounded at 40.5% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 14.4% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 27.1%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.17.

Recent Developments

  • Mar 2026 Revenue of ₹638.80 Cr (+28.4% YoY); net profit ₹172.89 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +28.4%, earnings +24.6%.
  • 5-Year Trend Long-term compounding — revenue CAGR 14.4%, profit CAGR 40.5%.

Growth & Price Performance

Compounded Sales Growth

5 Years:14.44%
1 Year:28.43%

Compounded Profit Growth

5 Years:40.51%
1 Year:24.63%

Stock Price Performance

1 Year:+72.01%
6 Months:+128.32%
3 Months:+79.56%
1 Month:+36.46%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 100% of range
₹529.06 ₹1,329.30
Trend Signals
  • Price vs 50-DMAAbove
  • RSI (14)85.39 · Overbought
Price Performance
1M+36.46%
3M+79.56%
6M+128.32%
1Y+72.01%
Valuation vs Sector

P/E of 85.76 is above the sector median of 41.64 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Healthy ROCE of 24.0%.
  • Excellent profit margin of 27.1%.
  • Compounding revenue at 14.4% over 5 years.
  • Profit CAGR of 40.5% over 5 years.

CONS

  • Trading at a high P/E of 85.8.
  • RSI at 85 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
85.76
Industry PE
41.64
Forward P/E
68.70
PEG Ratio
-
Book Value
₹78.21
Price to Book
12.24
P/S
16.84
EV/EBITDA
44.81
Dividend Yield
0.17%

Growth (CAGR)

Revenue 5Y
14.44%
Profit 5Y
40.51%
Revenue (YoY)
28.43%
Earnings (YoY)
24.63%

Profitability & Returns

ROCE
24.00%
ROE
19.57%
ROA
14.72%
Profit Margin
27.07%
Op Margin
32.62%
Gross Margin
63.11%
EPS (Latest Qtr)
₹3.59
EPS (TTM)
₹15.50

Balance Sheet & Liquidity

Debt/Equity
0.17
Quick Ratio
2.02
Current Ratio
3.09
Debt
₹150.42 Cr
Total Assets
₹1,174.88 Cr
Current Assets
₹623.97 Cr
Working Capital
₹422.00 Cr

Ownership

Promoter Holding
85.14%
Chg in Prom Hold
-0.47%
FII / Inst Holding
6.54%
Chg in FII Hold
0.06%

Financial Snapshot

Enterprise Value
₹15,014.26 Cr
Total Revenue (TTM)
₹638.80 Cr
EBITDA
₹248.33 Cr
Free Cash Flow
₹-48.60 Cr
Operating Cash Flow
₹69.55 Cr
Shares Outstanding
₹11.29 Cr
Gross Margin
63.11%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SUDEEPPHRM SUDEEP PHARMA LIMITED NSEPHARMA 1,329.30 85.76 ₹15,014.26 Cr 0.17% 24.00% 19.57% 14.44% 40.51%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,899.00 39.73 ₹4.56 L Cr 0.82% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,100.00 94.06 ₹2.42 L Cr 0.36% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,857.00 75.99 ₹1.64 L Cr 0.77% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,650.00 64.10 ₹1.24 L Cr 0.22% 19.20% 20.48% 14.85% 33.34%
6 LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA 684.90 236.17 ₹1.19 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,120.00 22.36 ₹1.13 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,385.00 28.85 ₹1.12 L Cr 0.88% 14.86% 11.27% 7.23% 11.45%
9 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 1,840.00 111.85 ₹99,333.61 Cr 0.13% 19.53% 16.77% 3.77% 4.00%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue 149.00 Cr-157.55 Cr124.92 Cr163.00 Cr172.34 Cr182.34 Cr158.27 Cr
Cost of Revenue --59.77 Cr42.32 Cr-60.19 Cr63.86 Cr56.59 Cr
Gross Profit --97.78 Cr82.60 Cr-112.14 Cr118.48 Cr101.68 Cr
Operating Expenses 85.00 Cr-41.83 Cr41.97 Cr107.00 Cr56.03 Cr59.77 Cr50.77 Cr
Operating Income 60.00 Cr-55.95 Cr40.62 Cr51.00 Cr56.11 Cr58.71 Cr50.91 Cr
EBITDA 63.00 Cr-62.54 Cr49.03 Cr55.00 Cr66.81 Cr69.02 Cr60.36 Cr
Interest Expense 1.00 Cr-1.85 Cr1.71 Cr2.00 Cr1.17 Cr2.44 Cr2.06 Cr
Pretax Income 62.00 Cr-57.85 Cr44.07 Cr60.00 Cr61.78 Cr62.69 Cr54.29 Cr
Tax Provision 13.02 Cr-13.67 Cr12.80 Cr12.60 Cr14.08 Cr14.15 Cr13.71 Cr
Net Income 49.00 Cr-44.19 Cr30.81 Cr47.00 Cr47.46 Cr48.88 Cr40.55 Cr
Diluted EPS 128.132.54-2.734.714.29-3.59

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 123.00 Cr215.00 Cr343.00 Cr426.17 Cr454.67 Cr497.41 Cr638.80 Cr
Cost of Revenue ---188.80 Cr172.30 Cr172.26 Cr235.63 Cr
Gross Profit ---237.37 Cr282.36 Cr325.15 Cr403.17 Cr
Operating Expenses 98.00 Cr171.00 Cr276.00 Cr153.44 Cr108.16 Cr144.19 Cr194.81 Cr
Operating Income 22.00 Cr40.00 Cr62.00 Cr83.93 Cr174.21 Cr180.96 Cr208.37 Cr
EBITDA 25.00 Cr44.00 Cr67.00 Cr97.30 Cr186.90 Cr198.09 Cr248.33 Cr
Interest Expense 1.00 Cr1.00 Cr2.00 Cr3.41 Cr3.06 Cr4.66 Cr5.44 Cr
Pretax Income 25.00 Cr43.00 Cr69.00 Cr85.98 Cr174.82 Cr182.85 Cr228.07 Cr
Tax Provision 6.75 Cr9.46 Cr18.63 Cr23.66 Cr41.63 Cr44.12 Cr53.79 Cr
Net Income 18.00 Cr33.00 Cr50.00 Cr62.32 Cr133.19 Cr138.73 Cr172.89 Cr
Diluted EPS 128.02236.60356.045.5211.7912.2815.50

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 131.00 Cr213.00 Cr344.00 Cr420.11 Cr513.87 Cr717.17 Cr1,174.88 Cr
Current Assets ---230.02 Cr275.37 Cr424.12 Cr623.97 Cr
Cash & Equivalents ---10.30 Cr13.98 Cr36.81 Cr26.74 Cr
Inventory ---71.00 Cr66.58 Cr128.67 Cr216.05 Cr
Receivables ---93.71 Cr144.57 Cr185.35 Cr227.54 Cr
Total Liabilities ---196.83 Cr157.83 Cr224.08 Cr276.78 Cr
Current Liabilities ---170.83 Cr137.22 Cr174.76 Cr201.96 Cr
Long Term Debt ---19.94 Cr11.14 Cr39.55 Cr34.29 Cr
Total Debt 20.00 Cr31.00 Cr84.00 Cr83.08 Cr78.08 Cr137.55 Cr150.42 Cr
Total Equity 81.00 Cr114.00 Cr163.00 Cr223.28 Cr356.03 Cr493.09 Cr883.34 Cr
Shares Outstanding ---11.29 Cr11.29 Cr11.29 Cr11.29 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow 10.00 Cr35.00 Cr-3.00 Cr48.40 Cr65.69 Cr48.73 Cr69.55 Cr
Investing Cash Flow -22.00 Cr-40.00 Cr-38.00 Cr-50.02 Cr-49.28 Cr-78.76 Cr-330.93 Cr
Financing Cash Flow 12.00 Cr13.00 Cr51.00 Cr-9.78 Cr-12.73 Cr52.70 Cr247.29 Cr
Capital Expenditure -9.00 Cr-11.00 Cr-74.00 Cr-47.15 Cr-52.46 Cr-64.23 Cr-118.15 Cr
Free Cash Flow 1.00 Cr24.00 Cr-77.00 Cr1.24 Cr13.22 Cr-15.51 Cr-48.60 Cr
Net Change in Cash -08.00 Cr10.00 Cr-11.40 Cr3.67 Cr22.67 Cr-14.09 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % ---55.7%62.1%65.4%63.1%
Operating Margin % 17.9%18.6%18.1%19.7%38.3%36.4%32.6%
Net Margin % 14.6%15.3%14.6%14.6%29.3%27.9%27.1%
ROE % 22.2%28.9%30.7%27.9%37.4%28.1%19.6%
ROCE % ---33.7%46.3%33.4%21.4%

Shareholding Pattern

Insiders
85.14%
Institutions
6.54%
Public Float
44.03%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SUDEEPPHRM

Google News Sun, 19 Jul 2026

SUDEEPPHRM Stock Price and Chart — NSE:SUDEEPPHRM - TradingView

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTFBFQUwzcGI0Q1duX0ZwX0pEN3lNX2Y1cUFhRElJQmE2WUNDbTEzYVhjN0NlVUZTOUNlaEFCdGRkWExDSFVsZmMtUllfR0sxay0tZHpZQ2ZvU1BQSkExU3lPeA?oc=5" target="_blank">SUDEEPPHRM Stock Price and Chart — NS…

Google News hu, 25 Jun 2026

SUDEEPPHRM Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE9SSFpkWnVBYndfWWNDbk01ZmFuZ3ViQlF6OGF4TUp4OUphRlJfRjN4QzBKbm40NkdLY3BIT2s1T3ZWMEFvMVRmVGoyMW1waXNCZjB1bU5NYnZxUlFkX1ZITXgyZWRIeDZmR21oMGRpbXZ0clViOTFnNWE1RlBRZw?oc=5" target="_blan…

Google News ue, 01 Sep 2026

Sudeep Pharma Share Price: Fresh 52-Week High at Rs 1,257.20 - univest.in

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxPUXlRREtPcnVMaXliSVMzRE5ia2JzcG1WSFdZNjR1ZTFxd3FLRVI5S1d0ajFLQmFyMW5pbzNpdjhDNC1mUkhnMkZCZ1d1dmhaY2xoNFpwQlF1ZEcyNExMMk51djQxRVY5Zk5GZGxhVHpGQmY2aVRJTHJfUlZxNVg0WGdoWlRTX3NVNXc?oc…

Google News ue, 02 Jun 2026

Sudeep Pharma Ltd | Stock Share Price Live - MarketSmith India

<a href="https://news.google.com/rss/articles/CBMidEFVX3lxTE00dmxPRUl6YXBqdlE3X25ycS1oUTk2U3F6cEo5WV9MX2JUdXUtaUR4eTRBVEdjb3pjQklwUzNRNTNYUllIMllVcDVNTzhVUWI4TWFOSVpRMk44NXZ2RHA5OS01WmRsMFZuUC0zd3hyN19EdkdL?oc=5" target="_blank">Sudeep Phar…

Google News Mon, 15 Jun 2026

Sudeep Pharma (SUDEEPPHRM.NS) Surges 9.75%: Key Levels and Potential Trajectory - Quality Factor - vinanet.vn

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPYXVIR081SUNaN3hyNnlwR0h4UDN5TGJ5NXF2WkpNSk9fNlczQ1loNWVOMWV4S1Vyc3VUaEk4RDkwN0R1SFNkdG9NWVF5YS1Ob0JhYTBOM01EbEFwTHduM0lOMDVkM0wzMHU0V1hwenZ1b1ZxdGNRYVFHcDJQZWE3T0s2Xy1aZFhPZUtuYX…

Google News hu, 06 Aug 2026

SUDEEPPHRM Q2 2026 Earnings: 28.4% Revenue Surge Lifts EPS to ₹15.5 - Earnings Analysis - siam.in

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcDI5M0RJbHVyZWt4TlJuSlRyaW5zQVg5dFB6RTM0blBLdVEtVmhCWjhETFNvdkZnWlJnWEtiZGY3UDVVeXoxNUFrYjNpa3NDRDVtVXpPR0wzdXJnR3lsanVHZG9aamZXVWNEa3dTWUM4b0E3aVROTld3Nm9BcUNGeW5IR3VXeXNnYnlBZ1…

SUDEEPPHRM — Frequently Asked Questions

What is the current share price of SUDEEP PHARMA LIMITED (SUDEEPPHRM)?

As of 2026-09-08 04:53 IST, SUDEEP PHARMA LIMITED (SUDEEPPHRM) trades at ₹1,329.30 on NSE. Its 52-week range is ₹529.06 to ₹1,329.30.

What is the market capitalisation of SUDEEPPHRM?

SUDEEP PHARMA LIMITED (SUDEEPPHRM) has a market capitalisation of ₹15,014.26 Cr on NSE.

What is the P/E ratio of SUDEEPPHRM?

SUDEEPPHRM trades at a trailing price-to-earnings (P/E) ratio of 85.76. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 12.24.

Does SUDEEPPHRM pay a dividend?

SUDEEP PHARMA LIMITED (SUDEEPPHRM) currently offers a dividend yield of 0.17%.

What is the return on equity (ROE) of SUDEEPPHRM?

SUDEEPPHRM has a return on equity (ROE) of 19.57%. Its return on capital employed (ROCE) is 24.00%.

Is SUDEEPPHRM a good stock to buy?

This page provides a data-driven analysis of SUDEEP PHARMA LIMITED (SUDEEPPHRM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space